The RET proto-oncogene has been well-studied. RET is involved in many different
physiological and developmental functions. When altered, RET mutations influence disease …

Since the discovery in 2012 of rearranged during transfection proto-oncogene gene (RET)
rearrangements in NSCLC, at least 12 different fusion variants have been identified, with …

Small cell lung carcinoma (SCLC) is a high-grade pulmonary neuroendocrine tumor. The
transcription factors ASCL1 and NEUROD1 play crucial roles in promoting malignant …

Small cell lung cancer (SCLC) is one of the four major histological types of lung cancer. The
incidence of SCLC in developed countries has declined in recent years, presumably …

Small cell lung cancer (SCLC) comprises about 15% of all lung cancers. It is an aggressive
disease, with early metastasis and a poor prognosis. Until recently, SCLC treatment …

The majority of small cell lung cancer (SCLC) patients demonstrate initial chemo-sensitivity,
whereas a distinct subgroup of SCLC patients, termed chemo-refractory, do not respond to …

KRAS mutations are one of the most prevalent oncogenic alterations in cancer. Until
recently, drug development targeting KRAS did not convey clinical benefits to patients …

Small cell lung cancer (SCLC) is an aggressive malignancy with a distinct natural history
and dismal prognosis. Given its predisposition for early dissemination, patients are …

Simple Summary Changes in the RET gene (like mutations or fusions) are often found in
lung and thyroid cancers but are also found in other cancer types. New drugs called …

The advent of tyrosine kinase inhibitors (TKIs) targeted therapy revolutionized the treatment
of chronic myeloid leukemia (CML) patients. However, cardiotoxicity associated with these …